Fig. 5.

8p11.22 amplification is associated with PDAC metastasis. A Heatmap illustrating the different metastatic sites, genomic alternations, biological pathways and xCell signatures of PDAC metastatic patients and non-metastatic patients (Fisher’s exact test). B 8p11.22 amplification in PDAC metastatic patients and non-metastatic patients (Fisher’s exact test). C The heatmap indicating the cis-effects of ADAM9 and PLEKHA2 at chromosome locus 8p11.22 (Spearman’s correlation). D The forest plot indicating the hazard ratio of ADAM9 and PLEKHA2 in Fudan cohort and CPTAC cohort. E The schematic work flow of transwell migration assay to evaluate the role of ADAM9 in promoting tumor cell metastasis. F The bar plots indicated the migrated cell counts of PANC-1 cells under different treatments. G Representative images of migrated PANC-1 cells. Scale bar, 50 μm. H Spearman-rank correlation of the abundance of ADAM9 and epithelial cell migration (GSVA score) (Spearman’s correlation). I Heatmap of the relative abundance of epithelial-cell-migration-related proteins that are significantly associated with ADAM9 expression. The fold change of proteins average expression between tumors and NATs and the correlation coefficient with ADAM9 are shown on the right. J The percent of metastatic patients and non-metastatic patients in high ADAM9/low CDCP1 and high ADAM9/high CDCP1 groups (Fisher’s exact test). K Spearman-rank correlation of the abundance of CDCP1 and SRC (upper). The heatmap on the bottom depicts the CDCP1 and SRC protein expression (bottom) (Spearman’s correlation). L Spearman-rank correlation of the abundance of SRC and WNT signaling pathway (GSVA score). M Flow chart for identification of SRC substrates that are significantly positively correlated with SRC expression. N Heatmap of the relative abundance of WNT-signaling-related proteins that are significantly associated with SRC expression (left). Spearman’s correlation is showed on the right. O The protein–protein interaction networks describing the interactions between ADAM9 and proteins involved in tumor microenvironment and between CDCP1 and proteins enriched in WNT signaling pathway. P Representative immunohistochemical staining pattern for ADAM9 and CDCP1 proteins on three tumor samples of metastatic patients. Q Representative immunohistochemical staining pattern for ADAM9 and CDCP1 proteins on two tumor samples of non-metastatic patients. ****p < 1.0E−4, ***p < 1.0E−3, **p < 1.0E−2, *p < 0.05, ns > 0.05